Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide.
Tewari
Prerna
P
Kenny
Elaine
E
Staines
Anthony
A
Chanock
Stephen
S
Browne
Paul
P
Lawler
Mark
M
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D016022:Case-Control Studies; D004265:DNA Helicases / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D000072200:Ku Autoantigen; D015810:Linkage Disequilibrium; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D011379:Prognosis; D013792:Thalidomide / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000175:diagnosis* / Q000209:etiology / Q000235:genetics
D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D004265:DNA Helicases; C106893:XRCC5 protein, human; D000072200:Ku Autoantigen